• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12B filed by BriaCell Therapeutics Corp.

    4/24/25 3:46:42 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCTX alert in real time by email
    8-A12B 1 form8a12b.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-A

     

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR (g) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    BriaCell Therapeutics Corp.

    (Exact name of registrant as specified in its charter)

     

    British Columbia   47-1099599
    (State or other jurisdiction
    of incorporation or organization)
      (I.R.S. Employer
    Identification No.)
         
    Suite 300 – 235, 15th Street, West Vancouver, BC Canada   V7T 2X1
    (Address of principal executive offices)   (Zip Code)

     

    Securities to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class to be so registered

     

    Name of each exchange on which each class is to be registered

    Warrants to purchase common shares, no par value

      The Nasdaq Stock Market LLC

     

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

     

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

     

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

     

    Securities Act registration statement or Regulation A offering statement file number to which this form relates: 333- 333-286670

     

    Securities to be registered pursuant to Section 12(g) of the Act: None.

     

     

     

       

     

     

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

     

    Item 1. Description of Registrant’s Securities to be Registered.

     

    The description of the warrants to purchase common shares of BriaCell Therapeutics Corp. (the “Registrant”) under the heading “Description Of Securities—Warrants to be Issued in this Offering” in the prospectus included in the Registrant’s Registration Statement on Form S-1 (File No. 333-286670), filed with the Securities and Exchange Commission on April 22, 2025, as amended on April 23, 2025, including the exhibits thereto (the “Registration Statement”), is hereby incorporated by reference. Any form of prospectus that constitutes part of the Registration Statement and is subsequently filed by the Registrant pursuant to Rule 424(b) under the Securities Act of 1933, as amended, shall be deemed to be incorporated by reference herein.

     

    Item 2. Index to Exhibits.

     

    The following exhibits have been filed as exhibits to the Registration Statement and are incorporated herein by reference:

     

    Exhibit No.   Description
    3.1   Articles of BriaCell Therapeutics Corp., dated July 26, 2006 (incorporated by reference to Exhibit 3.1 to our Registration Statement on Form F-1 filed with the SEC on October 22, 2019)
         
    3.2   Notice of Articles, dated November 25, 2014 (incorporated by reference to Exhibit 3.2 to our Registration Statement on Form F-1 filed with the SEC on October 22, 2019)
       
    3.3   Notice of Articles, dated August 22, 2019 (incorporated by reference to Exhibit 3.4 to our Registration Statement on Form F-1 filed with the SEC on June 15, 2021)
       
    3.4   Alteration to Articles filed February 13, 2023 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on February 15, 2023)
       
    3.5   Notice of Articles filed August 31, 2023 (incorporated by reference to Exhibit 3.1 to Form 8-K filed with the SEC on September 7, 2023)
       
    3.6   Notice of Articles filed August 31, 2023 (incorporated by reference to Exhibit 3.2 to Form 8-K filed with the SEC on September 7, 2023)
       
    4.1*   Form of Warrant
         
    10.1*   Form of Warrant Agent Agreement
         
    *   Filed herewith.

     

       

     

     

    SIGNATURES

     

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

     

      BriaCell Therapeutics Corp.
         
    Date: April 24, 2025 By: /s/ William V. Williams
        William V. Williams
        Chief Executive Officer

     

       

    Get the next $BCTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BCTX

    DatePrice TargetRatingAnalyst
    2/14/2022$25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

      HC Wainwright & Co. initiated coverage of BriaCell Therapeutics with a rating of Buy and set a new price target of $25.00

      2/14/22 6:04:45 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      5/20/24 4:00:14 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      12/28/22 4:38:08 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Williams William V.

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      12/28/22 3:22:52 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

      4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

      5/20/24 4:00:14 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer

      Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor Review marks third consecutive positive recommendation by DSMBStudy is being conducted under FDA Fast Track Designation PHILADELPHIA and VANCOUVER, British Columbia, June 24, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to report that the independent Data Safety Monitoring Board (DSMB) has completed its third scheduled safety data review of Bria

      6/24/25 7:30:25 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Announces Virtual Investor Presentations on Thursday, June 12 and Thursday, June 26

      PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces today that the Company will be conducting two virtual investor presentations on Thursday, June 12, at 12:00 PM EDT and on Thursday, June 26, at 12:00 PM EDT, arranged by Renmark Financial Communications Inc. Briacell Therapeutics Corp. welcomes stakeholders, investors, and other individual followers to register and attend these live events. Investors interested in participating in this event will need to re

      6/4/25 7:30:50 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BriaCell Reports Robust Overall Survival and Clinical Benefit Data at ASCO 2025

      Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC)Median Overall Survival of 17.3 months in Phase 2 study patients treated with Phase 3 formulation (since 2022) is superior to outcomes reported for comparable patients in the literatureMeaningful Clinical Benefit observed in all MBC subtypes, including HER2+, HR+/HER2-, and triple-negative breast cancer (TNBC)Overall survival and clinical benefit data reported meets or exceeds that of FDA-approved therapies in comparable patientsNo treatment-related discontinuations PHILADELPHIA and VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWS

      6/2/25 7:30:00 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BCTX
    SEC Filings

    See more
    • BriaCell Therapeutics Corp. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)

      6/18/25 8:27:34 AM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by BriaCell Therapeutics Corp.

      10-Q - BriaCell Therapeutics Corp. (0001610820) (Filer)

      6/16/25 4:34:51 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by BriaCell Therapeutics Corp.

      SCHEDULE 13G/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

      5/13/25 9:08:52 PM ET
      $BCTX
      Biotechnology: Pharmaceutical Preparations
      Health Care